Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Other Accumulated Expenses (2016 - 2025)

Cumberland Pharmaceuticals' Other Accumulated Expenses history spans 16 years, with the latest figure at $12.6 million for Q4 2025.

  • For Q4 2025, Other Accumulated Expenses rose 3.14% year-over-year to $12.6 million; the TTM value through Dec 2025 reached $12.6 million, up 3.14%, while the annual FY2025 figure was $12.6 million, 3.14% up from the prior year.
  • Other Accumulated Expenses for Q4 2025 was $12.6 million at Cumberland Pharmaceuticals, up from $10.1 million in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $17.6 million in Q4 2022 and bottomed at $7.6 million in Q3 2021.
  • The 5-year median for Other Accumulated Expenses is $12.3 million (2022), against an average of $12.3 million.
  • The largest annual shift saw Other Accumulated Expenses fell 24.67% in 2021 before it skyrocketed 102.9% in 2022.
  • A 5-year view of Other Accumulated Expenses shows it stood at $8.7 million in 2021, then surged by 102.9% to $17.6 million in 2022, then decreased by 8.03% to $16.2 million in 2023, then decreased by 24.26% to $12.3 million in 2024, then increased by 3.14% to $12.6 million in 2025.
  • Per Business Quant, the three most recent readings for CPIX's Other Accumulated Expenses are $12.6 million (Q4 2025), $10.1 million (Q3 2025), and $10.1 million (Q2 2025).